Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hematology Am Soc Hematol Educ Program ; 2023(1): 737-744, 2023 Dec 08.
Artigo em Inglês | MEDLINE | ID: mdl-38066933

RESUMO

Hematologists are often needed to assist with the management of microangiopathic emergencies in pregnancy. A firm understanding of the diagnosis and management of preeclampsia with severe features, hemolysis elevated liver enzyme and low platelet syndrome, and disseminated intravascular coagulation, which are the most common causes of microangiopathic emergencies, is critical. However, being able to consider when other microangiopathic emergencies (acute fatty liver of pregnancy, congenital and acquired thrombotic thrombocytopenic purpura, complement mediated microangiopathy, antiphospholipid syndrome) should be considered is imperative. The hematologist and obstetric team should work together to optimize the care of common as well as rare hematologic emergencies.


Assuntos
Síndrome HELLP , Síndrome Hemolítico-Urêmica , Pré-Eclâmpsia , Púrpura Trombocitopênica Trombótica , Gravidez , Feminino , Humanos , Síndrome HELLP/diagnóstico , Síndrome HELLP/terapia , Pré-Eclâmpsia/diagnóstico , Pré-Eclâmpsia/terapia , Emergências , Púrpura Trombocitopênica Trombótica/diagnóstico , Síndrome Hemolítico-Urêmica/diagnóstico
2.
Am J Perinatol ; 37(8): 809-812, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32274772

RESUMO

The novel coronavirus disease 2019 (COVID-19) pandemic is causing a necessary, rapid adjustment within the field of obstetrics. Corticosteroid use is a mainstay of therapy for those women delivering prematurely. Unfortunately, corticosteroid use has been associated with worse outcomes in COVID-19 positive patients. Given this information, it is necessary that obstetricians adjust practice to carefully weigh the fetal benefits with maternal risks. Therefore, our institution has examined the risks and benefits and altered our corticosteroid recommendations. KEY POINTS: · Corticosteroid use is an important part of prematurity treatment because it provides benefit to the fetus.. · Corticosteroid use may be related with increased morbidity and mortality in novel coronavirus disease 2019 (COVID-19).. · Therefore, during the COVID-19 pandemic, an alteration in current corticosteroid practices is necessary to uniquely weigh the maternal risks and fetal benefits..


Assuntos
Betametasona , Infecções por Coronavirus , Dexametasona , Maturidade dos Órgãos Fetais/efeitos dos fármacos , Pandemias , Pneumonia Viral , Complicações Infecciosas na Gravidez , Nascimento Prematuro/prevenção & controle , Cuidado Pré-Natal/métodos , Betacoronavirus/isolamento & purificação , Betametasona/administração & dosagem , Betametasona/efeitos adversos , COVID-19 , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/terapia , Dexametasona/administração & dosagem , Dexametasona/efeitos adversos , Feminino , Idade Gestacional , Glucocorticoides/administração & dosagem , Glucocorticoides/efeitos adversos , Humanos , Pneumonia Viral/diagnóstico , Pneumonia Viral/terapia , Gravidez , Complicações Infecciosas na Gravidez/terapia , Complicações Infecciosas na Gravidez/virologia , Medição de Risco , SARS-CoV-2
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...